COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mesenchymal Stem Cells for Radiation-induced Xerostomia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03876197
Recruitment Status : Enrolling by invitation
First Posted : March 15, 2019
Last Update Posted : October 22, 2020
Information provided by (Responsible Party):
Charlotte Lynggaard, Rigshospitalet, Denmark

Brief Summary:
A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.

Condition or disease Intervention/treatment Phase
Radiation Toxicity Xerostomia Due to Radiotherapy Dry Mouth Hyposalivation Mesenchymal Stem Cells Mesenchymal Stromal Cells Long Term Adverse Effects Biological: Autologous adipose-derived mesenchymal stem/stromal cells Other: Placebo Phase 1 Phase 2

Detailed Description:
This is a LTFU study to assess the long-term and late effects of treatment with MSCs or placebo given ultrasound-guided into the submandibular glands in subjects participating in the MESRIX trial. Study participants from the MESRIX trial will be invited for a clinical visit. The visit will include medical history, an ENT examination; measurements of the saliva production by sialometry, a Magnetic resonance imaging scan (MRI) and obtaining data on the patient-reported outcome with Xerostomia Questionnaire (XQ) and Visual-Analogue-Symptomatic scale (VAS). Subjects, who are not able or willing to attend a clinical visit, will be encouraged to fill out the Questionnaires online or on paper. If a study participant has deceased, information of the cause of death will be investigated in The Danish Register of Causes of Death

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Long-term follow-up of Randomized controlled trial MESRIX
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Follow-up Study of Safety and Efficacy in Subjects Who Participated in the Study of Intraglandular Mesenchymal Stem Cells in Patients With Radiation-induced Hyposalivation and Xerostomia (MESRIX)
Actual Study Start Date : August 1, 2020
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dry Mouth

Arm Intervention/treatment
Experimental: Autologous Adipose-derived mesenchymal stem cells
Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
Biological: Autologous adipose-derived mesenchymal stem/stromal cells
Autologous adipose-derived mesenchymal stem/stromal cells

Placebo Comparator: Placebo
2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
Other: Placebo
Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%

Primary Outcome Measures :
  1. Safety: Serious Adverse Events (SAEs) and new chronic diseases [ Time Frame: 5 years from randomization ]
    SAEs according to the ICH-GCP definition and new chronic diseases. For patients not attending the planned hospital visit consider searching The National Patient Register will be searched for registered SAEs. Number of patients

  2. Overall survival [ Time Frame: 5 years from randomization ]
    Overall survival is defined as the time from the intraglandular dose of the investigational product (MSCs or placebo) to the date of death or the date the subject is last known to be alive

  3. Relapse of oropharyngeal cancer [ Time Frame: 5 years from randomization ]
    Number of participants with relapse will be reported

  4. New malignancies [ Time Frame: 5 years from randomization ]
    Number of subjects who have new malignancies will be reported

  5. Zoonotic Diseases [ Time Frame: 5 years from randomization ]
    Number of subjects diagnosed Zoonotic Diseases will be reported

Secondary Outcome Measures :
  1. Patient-reported outcome measures-Health-related quality of life (HRQoL [ Time Frame: 5 years from randomization ]
    Xerostomia Questionnaire (XQ) ( Median item scores for each of the 8 questions will be reported (score range 0-10) and the XQ summary/composite score (0-100))

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Assessment of safety and treatment efficacy in subjects who were enrolled in the MESRIX Phase I/II clinical trial
  2. Subjects who were treated with either autologous mesenchymal stem cells or placebo
  3. Subjects who voluntarily decided to participate and signed the consent form after receiving explanations on the trial

Exclusion Criteria:

1. Subjects who were not enrolled in the MESRIX trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03876197

Layout table for location information
Department of Otolaryngology, University Hospital of Copenhagen
Copenhagen, Denmark
Sponsors and Collaborators
Rigshospitalet, Denmark
Layout table for investigator information
Principal Investigator: Charlotte Lynggaard, MD Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark
Layout table for additonal information
Responsible Party: Charlotte Lynggaard, Principal Investigator, Rigshospitalet, Denmark Identifier: NCT03876197    
Other Study ID Numbers: CVB2019-1
2014-004349-29 ( EudraCT Number )
First Posted: March 15, 2019    Key Record Dates
Last Update Posted: October 22, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Charlotte Lynggaard, Rigshospitalet, Denmark:
Xerostomia Due to Radiotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Long Term Adverse Effects
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Pathologic Processes